Patho final exam review (Module 1-Medicinal Chemistry) Flashcards

(62 cards)

1
Q

define pharmacophore

A

drugs that bind to the same target share a similar structural motif-this motif is necessary for binding to the receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

define the structure-activity relationship

A

properties of a drug depend on the chemical constituents of the molecule–by modifying the structure one can change the drug properties

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

list chemical properties of drugs that can be deduced from the structure and ones that affect their biological activities, ones that are affected by the change in pH

A

-pH affects ionization
structure [size, ionization, solubility, hydrophobicity, stereochemistry]
activity [membrane permeability, target binding, metabolism, excretion]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

identify ionizable groups in drug structures

A

weak acids and bases pka less than or higher than 7
-rings, carboxyls, phenol, guanidine, alkyl amines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

estimate the degree of drug ionization at a given pH using Henderson-Hasselbalch equation

A

pH<pKa is more acidic and more in acid form; protonated
pH>pKa is more basic and more in basic form; deprotonated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Predict the range of pH where a drug would be more soluble in water

A

water is polar
-make more acidic to improve solubility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

At pH 6.4, what is the ration of this drug in the acid form (neutral) to that in the base form (negatively-charged)? ibuprofen pKa 4.4
A. 100:1
B. 10:1
C. 1:1
D. 1:10
E. 1:100

A

E. 1:100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the different modes of permeation into the body?

A

Intercellular junctions, Lipid cell membranes, Transporters, Endocytosis and exocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

identify hydrophobic and hydrophilic groups in a drug structure

A

hydrophobic- methyl, chloro, phenyl, hexyl, cyclohexyl
hydrophillic- alcohol, carboxylic acid, amine, ketone, amide, ester

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

identify hydrogen bond donors and acceptors in a drug structure

A

donors- OH,NH
acceptors- O,N

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

explain how logP values affect the ability of drugs to reach target sites

A

-orally active drugs are relatively small and moderately lipophilic; hydrophobic drugs are sticky and bind to its drug better to target
-logP values are usually between -1 and 4
logP < 0
logP = 0 equal distribution
logP > 0 drug factors octanol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

explain why the relationship of drug effectiveness versus logP is parabolic

A

the relationship is parabolic because too hydrophobic or not being hydrophobic both can inhibit drug activity the same amount

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

calculate logP of a drug molecule from the pi value of its constituent groups

A

ClogP
-hydrophobic groups increase LogP (+)
-hydrophilic groups decrease LogP (-)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

estimate logD using logP an pKa at a given pH

A

Drug HA is acidic with logP= 2 and pKa=4
-at pH=1 D~P
-at pH=7 D«P
Drug B is a basic drug with logP= 2 and pKa=7
-at pH= 10 D~P
-at pH= D«P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Predict the efficiency of passive diffusion of a drug with a known pKa at a given pH

A

more neutral the compound is, the more can participate in passive diffusion
ratio of 1000:1 means 99.9% is neutral and can penetrate quicker/faster
equal concentration can cross at slower rate because only 0.1% is truly neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

predict where a drug will be absorbed in the digestive system based on the drug’s pKa value

A

drugs are absorbed in jejunum when pH is between 5-7
acidic drugs are absorbed in stomach where pH is 1-3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Define Hammett’s sigma values and estimate the electronic effects of substituent groups on drug ionization using hammett’s sigma values, also electron withdrawing and electron-donating groups

A

hammett’s sigma defines electronic effects on a functional group
positive sigma value- electron-withdrawing group (more acidic & lower pKa)
negative sigma value- electron-donating group (less acidic & higher pKa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what is the difference between inductive effect and resonance effect

A

withdrawing effect- negative charges can be stabilized and make molecule more acidic; effect becomes weaker by going through multiple bonds
(inductive effect)
resonance effect- observed with pi bonds, electronegative atoms with withdrawing effects, only occurs in ortho and para positions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how do electronic effects of substituent groups affect ionization, acidity and basicity

A

basic- electron-donating groups make the molecule more basic; electron-withdrawing make the molecule less basic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

determine R/S and E/Z notations for drugs from their structures

A

cis- Z (same side)
trans- E (against/across from eachother)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what are the differences between R/S, d/l, and D/L nomenclature systems

A

R/S -by absolute configuration, primary method for drugs. R (clockwise; right) S (counterclockwise; left)
d/l or +/- system- by optical rotation, experimentally determined, depends on solution condition
D/L- by relative configuration to glyceraldehyde; obsolete and only used for amino acids and sugars

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

list factors other than receptor binding that result in different biological properties of drug enantiomers

A

-permeation by transporters
-nonspecific binding to serum proteins
-metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

when a pair of stereoisomers are given, determine whether they are enantiomers, diastereomers, or geometric isomers

A

enantiomers- (1R, 2S) and (1S, 2R); (1R,2R) and (1S,2S)
diastereomers- (1R,2S) and (1R,2R); (1S,2R) and (1S,2S)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the KD value from a binding isotherm

A

KD- dissociation equilibrium constant
smaller the KD, the stronger the binding is
KD= (D)(R)/(DR)
When [D]=KD 50% of all receptors are occupied
When [D] &laquo_space;KD ~ 0
When [D]&raquo_space; KD ~ 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
calculate delta G(D) from KD & vice versa
DeltaG ~ -1.4 x LogKD (kcal/mol) 10^-6 (KD) = 8.4 (DG) 10^-7 (KD) = 9.8 (DG) 10^-8 (KD) = 11.2 (DG)
26
explain characteristics of type of interactions between drugs and receptors & types of interactions between drugs and receptors from a given structure
Hydrophobic interactions- attraction between nonpolar groups in water; most common type of interactions in protein-ligand complexes; surface area of nonpolar surface is reduced electrostatic interactions- attraction between +/- charges; water is a dipole, loves ions & dipoles can also be in proteins (backbone amide, a-helix) Hydrogen bonds- O and N;ionic H-bonds are stronger than neutral H-bonds aromatic rings- attractions are between electron-rich and electron-deficient regions (can be affected by EWG and EDGs) pi stacking- parallel stacking of aromatic rings T stacking- edge to face Cation-pi interaction- Interaction between a positive charge and an aromatic ring
27
explain the concept of QSARS (quantitative structure-activity relationships)
if you change structure you change the activity; uses mathematics to describe structure activity relationships and can tell roughly if new drug is better or not
28
antimetabolities, structure-based drug design, High-throughput screen, Isosteric replacement, Prodrugs
antimetabolites- analogs of endogenous metabolites (can act as inhibitors). will compete with a metabolite in reactions structure-based drug design- drug designed based on 3-D structure of a target protein Isosteric replacement- improves pharmacokinetics, improve selectivity, reduce side effects, simplify the synthesis process, avoid patent issues (groups not in pharmacophore are replaced with bioisostere) Prodrug- inactive or carrier form of a drug that is transformed in vivo (enzymatically) to the active drug form (prolong/shorten duration of drug, localize drug to a specific target site, advantage of active transport process, formulation problem, decrease toxicity, side effects)
29
bioisoteres explain their uses
functional groups/atoms with similar steric and electronic properties with similar effects too
30
pharmacology, pharmacodynamics & pharmacokinetics
Pharmacology- science of interactions of chemical compounds with biological systems Pharmacodynamics- the study of the biochemical and physiological effects of drugs and the mechanisms of their actions Pharmacokinetics- the study of absorption, distribution, biotransformation, and elimination of xenobiotics
31
identify the sites of drug actions (including receptors)
types of drug interactions- Orthosteric: agonist, antagonist, partial agonist, inverse agonist allosteric- PAMs,NAMs -extracellular, intracellular, on the cell surface
32
law of mass action & receptor occupancy
-law of mass action defines drug-receptor interaction -effect of a drug is directly proportional to the amount of drug-receptor complex formed rate of association =Kon [D][R] rate of dissociation =Koff [DR] KD (dissociation constant) -the LOWER the KD the HIGHER the affinity -KD is the concentration of ligand that will bind half the receptors at steady state
33
outline components in a receptor binding assay
receptor + radio-labeled ligand then filtered -non-specific line on binding analysis radio-labeled ligand competes for same sight as normal ligand
34
principles of receptor binding to measure affinity
how tightly it binds -sometimes 100% binding is not best option -can use data to get IC50 and then use cheng-prusoff to get Ki
35
graphical data for pharmacological profiling
can test several unlabeled compounds to compute Ki for each compound -can calculate rank affinity CHENG-PRUSOFF: Ki=IC50/[1+L/KD]
36
apply receptor affinity to receptor selectivity
affinity can be used to show selectivity but best affinity for something does not mean best selectivity -determined by ratio -higher number means higher selectivity
37
describe the relevance of Bmax to drug action
Bmax is an estimated number of receptors in a given tissue -values are determined through saturation binding studies -are independent of the ligand -can influence downstream signaling events
38
Identify and differentiate between the five classes of receptors
intracellular receptor transmembrane receptor RTKs; cytokine receptors Ion channel GPCRs
39
describe the effects of allosteric modulators on ion channels and GPCRs
lots of allosteric binding sites on these molecules to allow for changes to the receptor and its binding (can have inhibitory effect)
40
describe the features for G protein activation
-extracellular ligand is detected by the cell-surface receptor (R) -receptor triggers activation of G protein (G) -activate G protein changes activity of the effector (E) can be enzyme or ion channel
41
effects of subtypes of G proteins
Ga(stimulatory)-activates adenylyl cyclases, inhibits Src family tyrosine kinases Ga(inhibitory)-inhibits adenylyl cyclases, activates phosphodiesterases Ga(q/11)- activates Phospholipase C Ga(12/13)- recruits Rho guanine exchange factors(RhoGEFs) Gby- inhibits adenylyl cyclase, recruits GRK2&3, activates PI3Ky, ion channels (Ca and K)
42
compare signaling of the second messengers and arrestin
Second Messengers: cAMP (adenylyl cyclase effector enzyme) Phospholipase C (PLC) results in release of phosphoinositides and diacylglycerol cGMP effector enzyme is guanyl cyclase B arrestins serve as an adaptor protein to link activated GPCRs to MAP kinase pathway B-arrestin can uncouple receptor from G protein (desensitization) also endocytosis (recycling, lysosomal degradation) and signaling
43
describe the mechanism and consequence of receptor desensitization
Heterologous desensitization involves the activation of one GPCR can result in the inhibition of another (Gi-linked) Homologous desensitization involves only the activated GPCRs are "turned off" or desensitized
44
assess ligand-receptor concentration response curves for functional selectivity
functional selectivity requires that the receptor couple to multiple signal transduction pathways (G protein & B arrestin) *Prefers one pathway heavily over others but can do multiple pathways (biased)
45
use of the concept of functional selectivity to design better drugs
can be used to avoid a certain pathways and its negative effects with the drug
46
What is the difference between agonist and antagonist binding
-binding of agonist results in induced fit that activates the receptor -binding of an antagonist results in a different induced fit that does not activate the receptor
47
identify and compare dose response curves for each type of ligand in the "ligand spectrum"
full inverse agonist -100% silent antagonist- 0% full agonist- 100% super agonist- 100+%
48
use graphical data to compare potency and efficacy for active ligands
potency- dose of a drug required to produce a particular effect of given intensity efficacy- biological response resulting from the drug-receptor interaction is termed efficacy strong agonist has high affinity and high efficacy
49
describe the concept of a partial agonist
produces a reduced response even at full receptor occupancy, will not produce same maximal effect as a full agonist regardless of concentration
50
apply the concept of partial agonist theory to managing drug therapy
as more partial agonists are added to the mixture, full agonists are being displaced which can help in drug therapy to give appropriate response
51
describe the features of an inverse agonist
-produces opposite response of an agonist -full and partial inverse agonists both exist -stabilizes inactive form of the receptor
52
compare reversible competitive and irreversible, non-competitive inhibition
competitive (REVERSIBLE) -antagonist combines with the same site on the receptor as the agonist; antagonism can be reversed by increasing the dose of the agonist noncompetitive (partially reversible) -antagonist produces its effect at a site of the receptor other than the site used by the agonist; agonist and noncompetitive antagonist do NOT compete with eachother for single binding site IRREVERSIBLE antagonist- will usually bind to the same site as the agonist, will not be readily displaced-generally caused by covalent reaction between antagonist and receptor
53
use the concept of spare receptor to explain drug action
-maximal response is achieved without 100% occupancy of available receptors -important in action of irreversible antagonists (heart, brain, etc.) -system/tissue dependent; cells can have lots of reserve or none
54
describe functional and chemical antagonism
-functional antagonism: two drugs influence a physiological system but in opposite directions; both drugs can elicit response at same time -chemical antagonism: chemical reaction occurs between an agonist and an antagonist to form an inactive product; agonist is inactivated proportionally to the extent of the chemical reaction with the antagonist
55
describe the mechanisms of allosteric modulators and their potential benefit in drug therapy
-bind at sites unique from the agonist/antagonist -PAMs can increase potency, efficacy -NAMs can decrease potency, efficacy
56
define the key means by which drug effect is quantified and compared (onset, intensity, duration)
onset- when the drug starts its effects (MEC) duration of action- how long the drug is active Intensity- peak effect
57
know the differences between a quantal vs graded drug response
quantal response- all-or-none dose-response relationships (anaphylaxis or not; sedated or not) graded drug response- depends on dose and shows progressively increasing effects with increasing concentrations of the drug
58
calculate and compare the therapeutic index between drugs
Therapeutic index= TD50/ED50 TD50 is toxic side effect ED50 is therapeutic effect
59
describe the factors that modify the effects of drugs
-Drug tolerance (occurs by either drug disposition/metabolic tolerance or cellular/pharmacologic tolerance)
60
compare and contrast drug disposition tolerance and pharmacologic tolerance
pharmacologic tolerance affects the normal reactivity of the receptor; downregulation of receptors; change in receptor affinity, etc. drug disposition tolerance affects effectiveness of drug
61
apply cross-tolerance to disease management
tolerance develops to one drug and is seen with drugs belonging to the same class; not always complete (basis for opioid rotation)
62
understand the bases for on-target and off-target adverse effects